Emcure Pharmaceuticals’ a wholly owned subsidiary -- Emcutix Biopharmaceuticals has signed exclusive in-licensing agreement with WiQo. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region.
PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience. Over 40,000 dermatologists and aesthetic doctors worldwide use WiQo’s patented formulas. Since 2011 over 8 million needle-free skin booster professional procedures have been performed globally.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
